• Company
• Keytruda, the primary treatment for esophageal cancer
• by Apr 4, 2022 06:07am

• Policy
• Based on PVA exclusion, the arithmetic average is 90%
• by Lee, Tak-Sun Apr 4, 2022 06:07am

• Policy
• To commercialize innovative new drugs/supply essential drugs
• by Lee, Jeong-Hwan Apr 3, 2022 04:25pm

• Company
• Export of Celltrion/Samsung bioepis exceed ₩10trillion
• by Chon, Seung-Hyun Apr 3, 2022 04:18pm

• Company
• MS anticancer drug Revlimid, RVD combined therapy benefits
• by Nho, Byung Chul Apr 3, 2022 04:13pm

• Company
• Revlimid's reimb extended…maintenance therapy remains
• by Eo, Yun-Ho Apr 1, 2022 06:04am

• Company
• Roche joins in competition for RET-targeted therapies
• by Apr 1, 2022 06:03am

• Policy
• The MFDS released a national lot release of Comirnaty
• by Lee, Hye-Kyung Mar 31, 2022 04:29pm

• Company
• Sandoz, launched a muscle relaxation antagonist with Ilsung
• by Mar 31, 2022 04:27pm

• Policy
• Roche RET target anticancer drug Gavreto, approved in Korea
• by Lee, Hye-Kyung Mar 31, 2022 04:23pm